Denna sida på svenska
Loading profile information...

Education

(2007-2013) Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute, William Hahn lab, Boston, USA

(2007) PhD in experimental tumor biology, Department of Oncology-Pathology, Karolinska Institutet (KI), Cancer Center Karoliska (CCK) “Molecular determinants of glioma subsets with distinct histology or sensitivity to signal transduction inhibitors”, supervisor Professor Arne Östman, Stockholm, Sweden

(2001) Master of Science in Biology at Uppsala University, Uppsala, Sweden

Academic honours, awards and prizes

(2015) Magnus Bergvalls stiftelse

(2014) Magnus Bergvalls stiftelse 

(2014) Karolinska Institutets Forskningsstiftelser

(2014) Best poster together with PhD student Min Guo at the Winterviken retreat for the depart of Oncology-Pathology, KI

(2008-2009) Sweden-American foundation post doc scholarship, 300000 SEK 

Publications

A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer
Sjöberg E, Meyrath M, Milde L, Herrera M, Lövrot J, Hägerstrand D, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2019;():-

Reduced Expression of PROX1 Transitions Glioblastoma Cells into a Mesenchymal Gene Expression Subtype
Goudarzi Km, Espinoza Ja, Guo M, Bartek J, Nistér M, Lindström Ms, et al
Cancer research 2018;78(20):5901-5916

Glioblastoma and glioblastoma stem cells are dependent on functional MTH1
Pudelko L, Rouhi P, Sanjiv K, Gad H, Kalderén C, Höglund A, et al
Oncotarget 2017;8(49):84671-84684

PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status
Roodakker Kr, Elsir T, Edqvist Phd, Hagerstrand D, Carison J, Lysiak M, et al
ONCOTARGET 2016;7(45):72431-72442

TRAF2 is an NF-kappa B-activating oncogene in epithelial cancers
Shen Rr, Zhou Ay, Kim E, O'connell Jt, Hagerstrand D, Beroukhim R, et al
ONCOGENE 2015;34(2):209-16

Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers
Hagerstrand D, Tong A, Schumacher Se, Ilic N, Shen Rr, Cheung Hw, et al
CANCER DISCOVERY 2013;3(9):1044-57

Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile
Hägerstrand D, He X, Bradic Lindh M, Hoefs S, Hesselager G, Ostman A, et al
Neuro-oncology 2011;13(11):1178-91

Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents
Uecker A, Sicker M, Beckers T, Mahboobi S, Hagerstrand D, Ostman A, et al
ANTI-CANCER DRUGS 2010;21(8):759-65

PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541
Hägerstrand D, Lindh Mb, Peña C, Garcia-echeverria C, Nistér M, Hofmann F, et al
Neuro-oncology 2010;12(9):967-75

Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker
Hägerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Hartman M, et al
Neuro-oncology 2008;10(1):2-9

Characterization of an imatinib-sensitive subset of high-grade human glioma cultures
Hägerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kastemar M, et al
Oncogene 2006;25(35):4913-22

Show all publications

Map

View map


Stockholm